EVA1A regulates fatty acid transporter CD36 in fatty liver disease
Metabolic Dysfunction-Associated Steatotic Liver Disease（MASLD） is characterized by excessive accumulation of lipids in hepatocytes and is closely associated…
How are GLP-1 drugs reshaping treatment for obesity, diabetes, and heart disease?
A sweeping Lancet review reveals how modern incretin-based drugs are reshaping treatment for obesity and diabetes, delivering powerful…
New study identifies the optimal exercise dose for reducing hepatic steatosis
Hepatic steatosis is a core pathological feature of metabolic dysfunction-associated steatotic liver disease (MASLD). It not only drives…
Understanding leptin’s dual function in MAFLD pathogenesis
Metabolic dysfunction-associated fatty liver disease (MAFLD) has emerged as a predominant chronic liver condition globally, intricately linked with…
The vicious circle of aging and metabolic dysfunction-associated steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) and aging are locked in a vicious circle: senescence of…